Tactile Systems (TCMD) Q2 Revenue Up 8%

Tactile Systems Technology (TCMD) reported Q2 2025 GAAP revenue of $78.9 million, exceeding estimates and growing 7.8% year-over-year, primarily driven by a robust 52% surge in its airway clearance segment and a return to growth in lymphedema products. Despite an improved gross margin to 75%, GAAP net income and Adjusted EBITDA declined year-over-year due to a 13% increase in operating expenses stemming from strategic investments in sales and technology. The company slightly raised its full-year 2025 revenue and Adjusted EBITDA guidance, though profitability is expected to remain pressured in the near term as these investments continue, with a revised outlook anticipating slower lymphedema growth offset by higher airway clearance projections.

Analysis

Tactile Systems Technology (TCMD) reported a mixed but strategically significant second quarter for fiscal 2025. The company surpassed revenue expectations, delivering $78.9 million against a $73.9 million consensus, marking a 7.8% year-over-year increase. This outperformance was primarily fueled by a 52% surge in its airway clearance segment (AffloVest), signaling a critical shift in the company's growth drivers. While the core lymphedema product line, representing 84% of revenue, returned to growth, the company has lowered its full-year growth expectations for this segment from 8-10% to 4-5%. Despite an improved GAAP gross margin of 75%, profitability was a key concern as GAAP net income and Adjusted EBITDA declined 25.1% and 15.4% year-over-year, respectively. This was a direct result of a deliberate 13% increase in operating expenses, allocated to strategic investments in sales force expansion and technology implementation. Management's decision to slightly raise full-year revenue and Adjusted EBITDA guidance, while simultaneously investing heavily and completing a $30.0 million share repurchase, underscores a confidence in this 'invest-to-grow' strategy, though it signals continued margin pressure in the near term.

Key Decisions for Investors

• Investors should monitor execution on the company's strategic investments, looking for evidence of improved sales force productivity and operating leverage in subsequent quarters to validate the current high-expense strategy.
• It is crucial to re-weight valuation models to reflect the changing business mix, with the high-growth airway clearance segment becoming a more significant driver than the maturing, slower-growth lymphedema business.
• Given the near-term margin compression from planned investments, investors with a shorter horizon should weigh the risk of continued earnings pressure, while long-term investors may view the current phase as a strategic repositioning for future growth.